{"id":93832,"date":"2026-08-03T17:56:01","date_gmt":"2026-08-03T08:56:01","guid":{"rendered":"https:\/\/japanir.jp\/en\/ir\/4582-20260803-01_wp_tender_offer\/"},"modified":"2026-08-03T17:56:01","modified_gmt":"2026-08-03T08:56:01","slug":"4582-20260803-01_wp_tender_offer","status":"publish","type":"ir_release","link":"https:\/\/japanir.jp\/en\/company\/company-4582\/ir\/4582-20260803-01_wp_tender_offer\/","title":{"rendered":"Monthly status of exercise of the 58th and 66th stock acquisition rights issued through third-party allocation (with exercise price adjustment clause)"},"content":{"rendered":"<p>Disclosure of the monthly exercise status of stock acquisition rights issued via third-party allocation. Includes a detailed table defining exercised shares, exercise amount, issued shares, and other items constituting the exercise status. Monitoring future exercise trends and dilution impact is important.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4582","jir_company_name":"SymBio Pharmaceuticals Limited","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-08-03","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4582-20260803-01.pdf","jir_short_summary":"Disclosure of the monthly exercise status of stock acquisition rights issued via third-party allocation. Includes a detailed table defining exercised shares, exercise amount, issued shares, and other items constituting the exercise status. Monitoring future exercise trends and dilution impact is important.","jir_summary":"### Section Heading\nThis disclosure reports the monthly status of exercise for the 58th and 66th stock acquisition rights (with exercise price adjustment clause) issued via third-party allocation. The body lists the number of issued shares, exercised shares, exercise amounts, per-date exercise status, and decimal rounding details in a tabular format. While not directly linked to financial indicators, it contains information important for assessing dilution prospects.\n\n### Section 2 Heading\nThe document presents both monthly aggregate exercise values and daily details, implying that future exercise trends could affect issued shares and dilution. In particular, attention should be paid to changes in issued shares, the number of rights, and the exercise amounts at each exercise event. It remains important to continue tracking applicable terms (e.g., exercise price adjustment clauses).","jir_financial_highlights":"Exercised shares: Unknown (Unknown)\nExercise price: Unknown (Unknown)\nIssued shares: Unknown (Unknown)","jir_category":"","jir_hashtags":"#SymBioPharmaceuticals, #IRUpdate, #JapanStocks","jir_key_figures":"Exercised shares: Unknown\nExercise price: Unknown\nIssued shares: Unknown","jir_meta_title":"\u3010SymBio Pharmaceuticals\u3011Notice of exercise status for stock acquisition rights\uff5cAugust 2026","jir_meta_description":"Notice on the monthly exercise status of third-party allocated stock acquisition rights. Discloses latest figures for exercised shares, exercise amounts, and issued shares. Important for confirming dilution impact.","jir_og_title":"SymBio Pharmaceuticals | Notice of stock acquisition rights exercise status (August 2026)","jir_og_description":"Discloses monthly stock acquisition rights exercise status. See exercised quantities, amounts, issued shares, etc. in a table.","jir_og_image_url":"\/assets\/og\/company-tender_offer.jpg","jir_chart_data_collection":"[]","ir_related_company":60013,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"tender_offer","footnotes":""},"sector":[],"importance":[],"class_list":["post-93832","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Monthly status of exercise of the 58th and 66th stock acquisition rights issued through third-party allocation (with exercise price adjustment clause) - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4582\/ir\/4582-20260803-01_wp_tender_offer\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4582\/ir\/4582-20260803-01_wp_tender_offer\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4582\/ir\/4582-20260803-01_wp_tender_offer\/\",\"name\":\"Monthly status of exercise of the 58th and 66th stock acquisition rights issued through third-party allocation (with exercise price adjustment clause) - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-08-03T08:56:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4582\/ir\/4582-20260803-01_wp_tender_offer\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4582\/ir\/4582-20260803-01_wp_tender_offer\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4582\/ir\/4582-20260803-01_wp_tender_offer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Monthly status of exercise of the 58th and 66th stock acquisition rights issued through third-party allocation (with exercise price adjustment clause)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Monthly status of exercise of the 58th and 66th stock acquisition rights issued through third-party allocation (with exercise price adjustment clause) - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4582\/ir\/4582-20260803-01_wp_tender_offer\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4582\/ir\/4582-20260803-01_wp_tender_offer\/","url":"https:\/\/japanir.jp\/en\/company\/company-4582\/ir\/4582-20260803-01_wp_tender_offer\/","name":"Monthly status of exercise of the 58th and 66th stock acquisition rights issued through third-party allocation (with exercise price adjustment clause) - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-08-03T08:56:01+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4582\/ir\/4582-20260803-01_wp_tender_offer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4582\/ir\/4582-20260803-01_wp_tender_offer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4582\/ir\/4582-20260803-01_wp_tender_offer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"Monthly status of exercise of the 58th and 66th stock acquisition rights issued through third-party allocation (with exercise price adjustment clause)"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"related_company_data":{"id":"60013","title":"SYMBIO PHARMACEUTICALS LTD","ticker":"4582"},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/93832","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/ir_release"}],"replies":[{"embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/comments?post=93832"}],"version-history":[{"count":0,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/93832\/revisions"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=93832"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=93832"},{"taxonomy":"importance","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/importance?post=93832"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}